144 related articles for article (PubMed ID: 35881329)
1. Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.
Patel H; Modi N; Chaudhari J; Patel P; Giri P; Patel H; Pandya V; Desai R; Jain M
Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):725-740. PubMed ID: 35881329
[TBL] [Abstract][Full Text] [Related]
2. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation.
Jain M; Joharapurkar A; Patel V; Kshirsagar S; Sutariya B; Patel M; Patel H; Patel PR
Eur J Pharmacol; 2019 Jan; 843():113-120. PubMed ID: 30458168
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
6. HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia.
Patel VJ; Joharapurkar A; Kshirsagar SG; Patel MS; Savsani HH; Dodiya HS; Rakhasiya MH; Kajavadara C; Valani D; Jain MR
Toxicol Appl Pharmacol; 2024 Feb; 483():116832. PubMed ID: 38266872
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
[TBL] [Abstract][Full Text] [Related]
8. Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress.
Joharapurkar AA; Patel VJ; Kshirsagar SG; Patel MS; Savsani HH; Jain MR
Drug Dev Res; 2021 Sep; 82(6):852-860. PubMed ID: 33480036
[TBL] [Abstract][Full Text] [Related]
9. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH
Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
[TBL] [Abstract][Full Text] [Related]
14. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
[TBL] [Abstract][Full Text] [Related]
15. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
Pasha MK; Jayaraman R; Reddy VP; Yeo P; Goh E; Williams A; Goh KC; Kantharaj E
Drug Metab Lett; 2012 Mar; 6(1):33-42. PubMed ID: 22372550
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
17. Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state.
Joharapurkar AA; Patel VJ; Kshirsagar SG; Patel MS; Savsani HH; Kajavadara C; Valani D; Jain MR
Curr Res Pharmacol Drug Discov; 2022; 3():100102. PubMed ID: 35570856
[TBL] [Abstract][Full Text] [Related]
18. Desidustat: First Approval.
Dhillon S
Drugs; 2022 Jul; 82(11):1207-1212. PubMed ID: 35834123
[TBL] [Abstract][Full Text] [Related]
19. In vitro drug metabolism and pharmacokinetics of a novel thiazolidinedione derivative, a potential anticancer compound.
S S; Vuppu S
J Pharm Biomed Anal; 2020 Feb; 179():113000. PubMed ID: 31787460
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals.
Hu ZY; Li XX; Du FF; Yang JL; Niu W; Xu F; Wang FQ; Li C; Sun Y
Acta Pharmacol Sin; 2013 Nov; 34(11):1437-48. PubMed ID: 24056706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]